^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL
Excerpt:
...4.Has been untreated for advanced disease except as follows: a.BRAF V600 mutation-positive melanoma may have received SOC targeted therapy as 1L therapy for advanced disease (eg, BRAF/MEK inhibitor, alone or in combination). ...
Trial ID:
Source:
Title:
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Excerpt:
...BRAF V600 mutation patients must have progressed on, or are intolerant to, BRAF +/- MEK inhibitor therapy....
Trial ID:
More C2 evidence
Source:
Title:
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Excerpt:
...Melanoma with known BRAFv600 mutation: received BRAF/MEKi therapy before this study....
Trial ID:
Source:
Title:
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
Excerpt:
...Both BRAF wild-type and mutated melanomas are eligible; BRAF mutated patients are required to have previously progressed on or...
Trial ID:
Source:
Title:
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
Excerpt:
...If BRAF mutated, patients must have progressed to treatment with BRAF inhibitors....
Trial ID:
Source:
Title:
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
Excerpt:
...Have received a combination of a BRAF inhibitor and a MEK inhibitor if diagnosed with a BRAF mutated melanoma and if clinically indicated; and 5....
Trial ID:
Source:
Title:
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Excerpt:
...Irrespective of PD-L1 result and BRAF V600 mutation 4....
Trial ID:
Source:
Title:
Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)
Excerpt:
...BRAF V600 mutant melanoma may have received standard of care targeted therapy (e.g....
Trial ID:
Source:
Title:
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
Excerpt:
...Consent to the evaluation of the PD-L1 status and BRAF V600 mutation status ; 7....
Trial ID:
Source:
Title:
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
Excerpt:
...- Has documented BRAF mutation status or is willing to provide a tumor tissue for BRAF genotyping....
Trial ID:
Source:
Title:
Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)
Excerpt:
...- Has testing for a BRAF mutation prior to study entry...
Trial ID:
Source:
Title:
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)
Excerpt:
...- Participants with BRAF gene mutant melanoma must have had a prior treatment regimen that included vemurafenib, dabrafenib, or an approved BRAF gene and/or mitogen-activated protein kinase (MEK) protein inhibitor...
Trial ID:
Source:
Title:
IMM60 and Pembrolizumab in Melanoma and NSCLC
Excerpt:
...B-type Raf proto-oncogene (BRAF) mutation status available -...
Trial ID:
Source:
Title:
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD1 or AntiPDL1 Antibodies
Excerpt:
...For subjects with known anaplastic lymphoma kinase (ALK), ROS proto- oncogene 1, receptor tyrosine kinase (ROS1) or epidermal growth factor receptor (EGFR) sensitizing molecular rearrangements, or with BRAF mutations, at least 1 line of targeted therapy will be required in addition to anti-PD-1/PD-L1 therapy.2. ...
Trial ID:
Less C2 evidence
Source:
Title:
Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy
Published date:
04/20/2022
Excerpt:
Advanced BRAF-mutant melanoma patients treated with 1L CPI or TT were selected from a real-world, electronic health record-derived database....CPI was associated with improved survival after adjustment for potential confounders (hazard ratio, 0.75 [95% CI, 0.66–0.87])....This real-world study demonstrated a survival benefit with 1L CPI versus TT.
DOI:
10.2217/fon-2021-1536
